Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Clinical staging of chronic lymphocytic leukemia

KR Rai, A Sawitsky, Cronkite Ep et al. · Blood · 1975 · 2.7K citations

Medicine, Hematology, Oncology +13

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

Cheson Bd, J M Bennett, Michael R. Grever et al. · Blood · 1996 · 1.8K citations

Medicine, Hematology, Oncology +12

Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia

Bercedis L. Peterson, Frederick R. Appelbaum, Jonathan E. Kolitz et al. · New England Journal of Medicine · 2000 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Michael J. Keating, Ian W. Flinn, Vinay Jain et al. · Blood · 2002 · 946 citations · Full text

Medicine, Oncology, Pharmacology +8

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Anders Österborg, Martin J.S. Dyer, Donald Bunjes et al. · Journal of Clinical Oncology · 1997 · 518 citations

Medicine, Oncology, Pharmacology +16